Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation
- 15 July 2002
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 100 (2) , 427-434
Abstract
There has not been a reported series of children with therapy-induced myelodysplastic syndrome/acute myeloid leukemia (tMDS/tAML) who were treated systematically. This paper describes 24 children with tMDS/tAML who were assigned randomly to standard- or intensive-timing induction on protocol CCG 2891. Presenting features and outcomes of those children were compared with those of 960 patients with de novo MDS (62 patients) or AML (898 patients). Children with tMDS/tAML were older at presentation (P = .015), had lower white blood cell counts (P = .01), and were more likely to have MDS (21% vs 7%) (P = .02) and trisomy 8 (P = .06). Fewer had hepatomegaly (P = .02), splenomegaly (P = .03), hepatosplenomegaly (P = .02), or classic AML translocations [t(8;21), t(15;17), 16q22; P = .02]. They had a poorer induction rate (50% vs 72%,P = .016), overall survival (26% vs 47% at 3 years,P = .007), and event-free survival (21% vs 39% at 3 years, P =.023). Disease-free survival after achieving remission was similar (45% vs 53%, P = .868). Children with tMDS/tAML who received intensive-timing induction had better outcomes than those who received standard-timing induction (overall survival 32% vs 0%, P = .54). In this study, the latency period to development of tMDS/tAML was the same for presumed alkylator-induced as for topoisomerase-induced myeloid leukemia. The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standard-timing induction appears less effective for this population.Keywords
This publication has 49 references indexed in Scilit:
- A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer GroupBlood, 2001
- THERAPY-RELATED MYELOID LEUKEMIAHematology/Oncology Clinics of North America, 1996
- Therapy‐related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risksMedical and Pediatric Oncology, 1994
- Therapy-related Myelodysplastic SyndromesHematology/Oncology Clinics of North America, 1992
- Epipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemiaCancer, 1991
- Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid LeukemiaNew England Journal of Medicine, 1989
- Second malignant neoplasms following childhood Hodgkin's disease: Treatment and splenectomy as risk factorsMedical and Pediatric Oncology, 1989
- Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimensBritish Journal of Cancer, 1987
- Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaAnnals of Internal Medicine, 1985
- Chromosome analysis of 63 cases of secondary nonlymphoid blood disorders: A cooperative studyCancer Genetics and Cytogenetics, 1984